v3.25.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:        
Net loss $ (11,706) $ (13,601) $ (16,690) $ (29,885)
Adjustments to reconcile net loss to net cash used in operating activities:        
Non-cash lease expense 6 (2) (9) 4
Depreciation and amortization 78 162 199 264
Stock-based compensation expense 864 1,302 1,724 2,414
Change in fair value of warrant liabilities (1,314) 233 (629) (1,704)
Other expenses representing transaction costs allocated to the issuance of warrants     574
Loss on impairment and disposal of property and equipment 25 (3) 28 64
Forgiveness of DECD loan (1,000) (1,000)
Financing expense for entering into 2023 Equity Line of Credit Agreement 258 258
Changes in operating assets and liabilities:        
Accounts receivable 205 (345) (214) (218)
Prepaid expenses and other assets 560 1,011 577 33
Inventories (63) 15 89 (142)
Accounts payable 1,290 501 380 (620)
Accrued liabilities (369) (313) (539) (1,838)
Other liabilities (668) (662) (68) (14)
Net cash used in operating activities (11,092) (12,444) (15,894) (31,068)
Cash flows from investing activities:        
Purchase of property and equipment (37) (12) (24) (232)
Net cash used in investing activities (37) (12) (24) (232)
Cash flows from financing activities:        
Principal repayment of DECD loan (35) (148) (148) (261)
Proceeds from issuance of common stock from exercise of stock options     13
Proceeds from issuance of common stock     202
Payment of stock issuance costs   (134)
Proceeds from equity line of credit     1,177
Proceeds from registered direct offering     4,716
Payment of issuance costs for registered direct offering     (597)
Proceeds from public offering     9,000
Payment of issuance costs for public offering     (1,325)
Net cash provided by financing activities 10,407 4,255 5,216 7,427
Net decrease in cash, cash equivalents and restricted cash (722) (8,201) (10,702) (23,873)
Cash, cash equivalents and restricted cash, beginning of the period 2,855 13,557 13,557 37,430
Cash, cash equivalents and restricted cash, end of the period 2,133 5,356 2,855 13,557
Cash and cash equivalents 2,133 5,100 2,597 13,306
Restricted cash 256 258 251
Cash and cash equivalents, and restricted cash 2,133 5,356 2,855 13,557
Supplemental disclosure of cash flow information:        
Cash paid for interest 43 41 45 77
Supplemental disclosure of noncash investing and financing activities:        
Increase in right-of-use assets 169 318 318
Fair value of warrants issued in conjunction with common stock offering     $ 3,984
Forgiveness of DECD loan (1,000)    
Fair value of Warrants issued in conjunction with Warrant Inducement Agreement 1,323    
Commitment shares for equity line of credit 258    
At The Market Offering Agreement [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 202    
Payment of stock issuance costs (134)    
Equity Line of Credit Agreement [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 1,901 178    
2023 Direct Offering [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 4,716    
Payment of stock issuance costs (559)    
2024 Direct Offering [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 5,563    
Payment of stock issuance costs (733)    
Warrant Inducement Agreement [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 2,139    
Payment of stock issuance costs (277)    
Securities Purchase Agreements [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 11    
Private Placement Offering [Member]        
Cash flows from financing activities:        
Proceeds from issuance of common stock 1,910    
Payment of stock issuance costs $ (72)